Transdermal absorption preparation containing apomorphine
By combining polyols and propylene carbonate, high concentration of apomorphine liquid was prepared, which solved the problem of insufficient dissolution of apomorphine, achieved rapid and continuous skin permeability, and improved the deadline symptoms of Parkinson's disease patients.
Patent Information
- Application Number
- CN202180036299.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-05-20
- Filing Date
- 2021-05-18
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2041-05-18
AI Technical Summary
The prior art is difficult to develop apomorphine dissolution method with a sufficiently high concentration, resulting in insufficient skin permeability at night and morning hours, which cannot effectively alleviate the symptoms of Parkinson's disease patients.
By combining specific polyols and propylene carbonate, liquids with high concentrations of apomorphine or their salts are prepared, combined with antioxidants, organic acids and emulsifiers, a percutaneous absorption formulation capable of rapid and continuous administration is prepared.
A high concentration of apomorphine dissolved and rapid continuous skin permeability were achieved, significantly improving the closing symptoms during night and morning periods, providing stable efficacy and low skin irritation.
Smart Images

Figure CN115666571B_ABST
Abstract
Description
Technical Field
[0001] (CROSS-REFERENCE TO RELATED APPLICATIONS)
[0002] This application claims the benefit of Japanese Patent Application No. 2020-87793 filed in the Japan Patent Office on May 20, 2020. The entire application documents (specification, claims, drawings, and abstract) of the Japanese application are as described in this specification and are incorporated herein by reference for the purpose of entirety.
[0003] The present invention relates to a percutaneous absorption preparation containing apomorphine or a salt thereof as an active ingredient, and more particularly to a percutaneous absorption composition containing apomorphine or a salt thereof at a high concentration and capable of percutaneously administering a sufficient amount of apomorphine for treatment. Background Art
[0004] Apomorphine is a dopamine D1-like and D2-like receptor agonist, which stimulates the receptors in the striatum and shows a rapid improvement effect on the OFF symptoms of Parkinson's disease. In particular, as a rescue drug for OFF symptoms caused by insufficient efficacy of L-DOPA, subcutaneous injection can be used clinically. For example, a pharmaceutical composition for injection containing 1) apomorphine as an active ingredient, 2) a water-soluble co-solvent, 3) an antioxidant, and 4) water, and having a pH of more than 4 is proposed (Patent Document 1).
[0005] However, for most patients, off-phase symptoms due to insufficient efficacy of L-DOPA occur not only during the day but also at night and in the morning when medication is difficult, interfering with sleep and activities when waking up.
[0006] Therefore, in order to improve the off-season symptoms occurring at night and in the morning, a transdermal absorption preparation that can be applied before going to bed and continuously administer apomorphine from bedtime until morning is desired.
[0007] In percutaneous absorption preparations for emergency treatment of nighttime and morning off-season symptoms, rapid and sustained skin permeability of apomorphine is required. In particular, in order to achieve rapid skin permeability after patch application, the drug is basically dissolved in the preparation at a high concentration. However, a method for dissolving apomorphine at a sufficient concentration has not yet been developed.
[0008] Prior art literature
[0009] Patent Literature
[0010] Patent Document 1: Japanese Patent Application Publication No. 2017-81947 Summary of the invention
[0011] An object of the present invention is to provide a transdermal absorption preparation which dissolves apomorphine or a salt thereof at a high concentration, thereby absorbing a sufficient amount of apomorphine for treatment in a short time and enabling continuous administration.
[0012] The present inventors have repeatedly conducted intensive studies to solve the above problems, and as a result, have found that a high-concentration apomorphine or salt-containing solution can be prepared by combining a specific polyol and propylene carbonate. Furthermore, the high-concentration apomorphine or salt-containing solution can be successfully used to prepare a preparation capable of transdermally administering a sufficient amount of apomorphine, thereby completing the present invention.
[0013] As the present invention, for example, the following aspects can be mentioned.
[0014] [1] A percutaneous absorption preparation comprising apomorphine or a salt thereof, a polyol having 6 or less carbon atoms and / or a low molecular weight polyethylene glycol, and propylene carbonate.
[0015] [2] The percutaneous absorption preparation according to [1] above, comprising 2% by weight or more of the apomorphine or a salt thereof.
[0016] [3] The percutaneous absorption preparation according to [1] above, comprising 4% by weight or more of the apomorphine or a salt thereof.
[0017] [4] The percutaneous absorption preparation according to any one of [1] to [3] above, wherein the propylene carbonate is contained in an amount within a range of 5% by weight to 40% by weight.
[0018] [5] The percutaneous absorption preparation according to any one of [1] to [4] above, wherein the total weight of the polyol and the low molecular weight polyethylene glycol is in the range of 1 to 10, with the weight of the propylene carbonate being 1.
[0019] [6] The percutaneous absorption preparation according to [5] above, wherein the polyhydric alcohol is one or more selected from propylene glycol, glycerol and 1,3-butylene glycol.
[0020] [7] The percutaneous absorption preparation according to any one of [1] to [6] above, further comprising an antioxidant.
[0021] [8] The percutaneous absorption preparation according to [7] above, wherein the antioxidant is sodium pyrosulfite.
[0022] [9] The percutaneous absorption preparation according to any one of [1] to [8] above, further comprising an organic acid or water.
[0023]
[10] The percutaneous absorption preparation according to [9] above, wherein the organic acid is isostearic acid or oleic acid.
[0024]
[11] The percutaneous absorption preparation according to any one of [1] to
[10] above, further comprising an emulsifier.
[0025]
[12] The percutaneous absorption preparation according to any one of [1] to
[11] above, wherein the dosage form is a liquid, a gel or an ointment.
[0026]
[13] A patch comprising the percutaneous absorption preparation according to
[12] impregnated with a carrier.
[0027]
[14] The percutaneous absorption preparation according to any one of [1] to
[12] or the patch according to
[13] , which is used for improving the off-season symptoms of Parkinson's disease.
[0028] According to the present invention, it is possible to provide a transdermal absorption preparation that can prepare a liquid containing apomorphine at a high concentration, absorb a sufficient amount of apomorphine from the skin into the body in a short period of time, and can continuously administer the apomorphine. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 The results of in vivo skin permeation tests of apomorphine hydrochloride using Franz cells are shown in Figure 2 for the preparations of Examples 1 to 3. The vertical axis represents the permeation amount (μg / cm 2 ), and the horizontal axis represents the elapsed time (hours). The numerical values (1.5, 3, and 5) in the figure represent the content (weight %) of apomorphine hydrochloride in the preparation.
[0030] Figure 2 The results of an in vivo skin permeation test of apomorphine hydrochloride using Franz cells for the preparation of Example 4 are shown in FIG. 2 ), and the horizontal axis represents the elapsed time (hours). The numerical value (10) in the figure represents the content (weight %) of apomorphine hydrochloride in the preparation. DETAILED DESCRIPTION
[0031] For the percutaneous absorption type preparation of the present invention, as an embodiment, it comprises apomorphine or its salt, polyol with carbon number 6 or less and / or low molecular weight polyethylene glycol, and propylene carbonate. The liquid comprising this combination can dissolve apomorphine or its salt at a high concentration of about 5% by weight or more or about 10% by weight. Even in the hydrophilic preparation prepared by further adding other ingredients to the high concentration solution, the concentration of apomorphine or its salt can be maintained at a sufficiently high concentration. In this way, a percutaneous absorption type preparation containing apomorphine or its salt with rapid and continuous skin permeability can be obtained.
[0032] For the percutaneous absorption type preparation of the present invention, apomorphine or its salt is included as an effective ingredient. The content of apomorphine or its salt in the percutaneous absorption type preparation of the present invention can be, for example, about 2% by weight or more, about 3% by weight or more, or about 4% by weight or more. The upper limit of the content of apomorphine or its salt can be, for example, about 15% by weight, about 12% by weight, or about 10% by weight. In one embodiment, the percutaneous absorption type preparation of the present invention does not include an effective ingredient other than apomorphine or its salt.
[0033] In one embodiment, apomorphine or its salt may include, for example, apomorphine free form, a salt of apomorphine and an organic acid, or a salt of apomorphine and an inorganic acid. It may also be apomorphine hydrochloride. In addition, apomorphine or its salt may be a hydrate or solvate of apomorphine free form or a salt of apomorphine.
[0034] In one embodiment, the percutaneous absorption preparation of the present invention may contain either a polyol having 6 or less carbon atoms or a low-molecular-weight polyethylene glycol alone, or both.
[0035] The amount of the polyol having 6 or less carbon atoms and the low molecular weight polyethylene glycol is not particularly limited as long as a sufficient amount of apomorphine or a salt thereof is dissolved, and the total amount may be, for example, about 20% by weight or more, about 30% by weight or more, about 40% by weight or more, about 50% by weight or more, or about 60% by weight or more of the percutaneous absorption preparation, or about 90% by weight or less, about 85% by weight or less, or about 80% by weight or less. From the viewpoint of skin permeability, the less the amount of the polyol having 6 or less carbon atoms and the low molecular weight polyethylene glycol, the better, and from the viewpoint of skin irritation, the more the better.
[0036] Here, the polyol having a carbon number of 6 or less (hereinafter referred to as "the polyol") is, for example, an alcohol having 2 to 8 or about 6 hydroxyl groups (OH), and there is no particular limitation as long as it is such a polyol. Examples of the polyol include diols and triols. The number of carbon atoms of the polyol may be, for example, 5 or less or 3 or less. Specifically, examples of the polyol include propylene glycol, 1,3-propylene glycol, 1,3-butylene glycol, 1,4-butylene glycol, pentanediol, hexanediol, and glycerol. Among them, propylene glycol, 1,3-butylene glycol, and glycerol are preferred. The percutaneous absorption preparation of the present invention may include one of these preparations, or any two or more of them.
[0037] When the polyol is glycerol (99% or more), the content can be, for example, in the range of about 1% to about 50% by weight, about 5% to about 40% by weight, or about 10% to about 30% by weight of the percutaneous absorption preparation. When the polyol is 1,3-butylene glycol, the content can be, for example, in the range of about 0.5% to about 30% by weight, or about 1% to about 25% by weight of the percutaneous absorption preparation. When the polyol is propylene glycol, the content can be, for example, in the range of about 1% to about 60% by weight, or about 3% to about 55% by weight of the percutaneous absorption preparation.
[0038] Examples of the low molecular weight polyethylene glycol include polyethylene glycol having a molecular weight of about 200 to about 600, and polyethylene glycol having a molecular weight of about 200 to about 300 can be used.
[0039] The amount of propylene carbonate may be, for example, in the range of about 1% to about 40% by weight, about 2% to about 30% by weight, or about 5% to about 25% by weight of the percutaneous absorption preparation.
[0040] Regarding the weight ratio of the polyol and / or low molecular weight polyethylene glycol to propylene carbonate, for example, when propylene carbonate is set to 1, the total of the polyol and the low molecular weight polyethylene glycol can be set in the range of about 1 to about 10, about 2 to about 9, or about 3 to about 8.
[0041] In one embodiment, the percutaneous absorption preparation of the present invention may contain an antioxidant. By adding an antioxidant, apomorphine or a salt thereof can be stored stably without coloring. Examples of the antioxidant include tocopherol acetate, sodium edetate, isoascorbic acid, 1,3-butylene glycol, butylated hydroxytoluene, ascorbic acid, propyl gallate, sodium sulfite, sodium pyrosulfite, and the like.
[0042] The content of the antioxidant is not particularly limited as long as stability of apomorphine or a salt thereof is achieved, and may be, for example, within a range of about 0.01% to 0.5% by weight, about 0.02% to 0.3% by weight, or about 0.05% to 0.2% by weight.
[0043] In one embodiment, the percutaneous absorption preparation of the present invention may contain an organic acid. By adding an organic acid, the skin permeability of apomorphine or its salt is improved. The type of the organic acid is not particularly limited, and examples thereof include oleic acid, isostearic acid, capric acid, sorbic acid, levulinic acid, lauric acid, myristic acid, palmitic acid, and stearic acid.
[0044] The content of the organic acid is not particularly limited as long as sufficient skin permeability of apomorphine or a salt thereof is obtained, and can be within the range of about 0.1% to about 5% by weight, about 0.2% to about 4% by weight, or about 0.3% to about 3% by weight of the percutaneous absorption preparation.
[0045] In one embodiment, the percutaneous absorption type preparation of the present invention may contain water. Thus, skin irritation can be reduced. The amount of water may be, for example, in the range of about 0.5% to about 30% by weight, about 1% to about 20% by weight, or about 2% to about 10% by weight of the percutaneous absorption type preparation.
[0046] In one embodiment, the percutaneous absorption preparation of the present invention may contain an emulsifier. By adding an emulsifier, when the percutaneous absorption preparation contains water, a substance with low solubility in water such as propylene carbonate and an organic acid can be stably dispersed in the liquid. Examples of the emulsifier include natural emulsifiers such as gum arabic, gelatin, tragacanth, lecithin (phosphatidylcholine), and cholesterol; anionic surfactants such as soap and sodium alkyl sulfate; polyoxyethylene sorbitan fatty acid esters such as monooleoyl polyoxyethylene sorbitan; glycerol fatty acid esters such as polyoxyethylene castor oil derivatives, polyoxyethylene hydrogenated castor oil, glycerol monostearate, and sorbitan monooleate; sorbitan fatty acid esters such as sorbitan monostearate and sorbitan sesquiester; polyoxyethylene higher alcohol ethers such as polyoxyethylene cetyl ether; nonionic surfactants such as polyoxyethylene alkylphenol and polyoxyethylene oxypropylene copolymers (e.g., Pluronic (registered trademark)); cationic surfactants such as cetyltrimethylammonium chloride; amphoteric surfactants, and the like.
[0047] In one embodiment, the percutaneous absorption preparation of the present invention may contain an alkanolamine. Examples of the alkanolamine include primary alkanolamines, secondary alkanolamines, or tertiary alkanolamines having 2 to 12 carbon atoms, and specifically, examples include diethanolamine, triethanolamine, diisopropanolamine, and triisopropanolamine. The content of the alkanolamine may be selected from, for example, about 0.005% to about 0.4% by weight, or about 0.01% to about 0.3% by weight of the percutaneous absorption preparation.
[0048] The percutaneous absorption preparation of the present invention may contain various additives used in external preparations or cosmetics as needed. Such additives include fragrances, antioxidants, preservatives, colorants, buffers, pH adjusters, ultraviolet absorbers, antibacterial agents, etc. Examples of preservatives include sorbic acid and taurine. Examples of pH adjusters include organic acids such as citric acid, acetic acid, and tartaric acid; and inorganic acids such as phosphoric acid and hydrochloric acid.
[0049] The final dosage form of the percutaneous absorption preparation of the present invention is not particularly limited. Examples of the dosage form include liquids, gels, ointments, and dosage forms in which at least one of these dosage forms is impregnated in a carrier. The percutaneous absorption preparation of the present invention is formulated into various external preparations that allow the drug to be absorbed from the skin and applied to the skin by coating or spraying. In addition, when the percutaneous absorption preparation of the present invention is, for example, a liquid or gel, it can also be applied by attaching a carrier (nonwoven fabric, foaming matrix, etc.) impregnated with the preparation to the skin. According to this method, the dosage can be easily adjusted and the operability is good.
[0050] The percutaneous absorption preparation of the present invention can be used as a so-called pharmaceutical product containing apomorphine or a salt thereof as an active ingredient. Since it is absorbed early and a lasting effect can be obtained, it can be used as an agent for improving the off-symptoms of Parkinson's disease, for example.
[0051] Example
[0052] Hereinafter, the present invention will be described in more detail with reference to Examples, but the present invention is not limited to the Examples.
[0053] 1. Study on the solubility of apomorphine hydrochloride
[0054] The solubility of apomorphine hydrochloride in various solvents was studied. The results are shown in Table 1.
[0055] When any one of water, 1,3-butylene glycol, polyethylene glycol, propylene glycol, glycerin, and propylene carbonate is used alone, the solubility of apomorphine hydrochloride is 3% by weight or less. In particular, the solubility in propylene carbonate is extremely low, at 0.25%.
[0056] On the other hand, if a low molecular weight polyethylene glycol and propylene carbonate are combined, an 8 wt% apomorphine hydrochloride solution can be prepared, and in the combination of propylene glycol and propylene carbonate, if a solvent mixed with propylene glycol in an amount of 5 times or more of the weight of propylene carbonate is used, a 10 wt% apomorphine hydrochloride solution can be prepared.
[0057] Similarly, even when a solvent in which 1,3-butanediol and concentrated glycerol (99%) were mixed with propylene carbonate at a weight ratio of 5:1 was used, 10% by weight of apomorphine hydrochloride could be prepared.
[0058] [Table 1]
[0059]
[0060] ○: Dissolved
[0061] ×: Crystals remain
[0062] -: Not implemented
[0063] BG: 1,3-Butanediol
[0064] PEG: polyethylene glycol
[0065] PG: Propylene glycol
[0066] GL: Concentrated glycerin
[0067] CP: Propylene carbonate
[0068] 2. Preparation of Apomorphine Hydrochloride Solution
[0069] According to the study in 1. above, a 1.5% solution (Example 1), a 3% solution (Example 2), and a 5% solution (Example 3) of apomorphine hydrochloride were prepared, which contained the polyol (propylene glycol, concentrated glycerol, and 1,3-butylene glycol) and propylene carbonate at a weight ratio of about 3.7:1 to about 3.5:1 (the polyol: propylene carbonate). In addition, a 10% solution of apomorphine hydrochloride (Example 4) containing a mixture of the polyol and a low molecular weight polyethylene glycol and propylene carbonate at a weight ratio of about 7.9:1 (the mixture: propylene carbonate) was prepared. The compositions (weight %) are shown in Table 2. In any of the examples, apomorphine hydrochloride was completely dissolved.
[0070] [Table 2]
[0071]
[0072] [Skin permeability test]
[0073] An in vivo skin permeation test using Franz cells was conducted on the preparations (patch) in which the liquid preparations of Examples 1 to 3 (percutaneous absorption preparations of the present invention) were impregnated with a carrier. The skin used for the test was extracted from the abdomen of 5-week-old hairless mice (male). The cumulative skin permeation (μg / cm 2 ) is shown in Figure 1 .
[0074] Although all the liquid preparations showed a continuous increase in the amount of skin permeation, there is still the following suggestion: for the liquid preparation containing 3% by weight or more of apomorphine hydrochloride, its transdermal absorption onset is rapid and the drug effect can be obtained in a short time.
[0075] Therefore, it is suggested that in order to obtain early skin permeability after administration, it is desirable to set the apomorphine hydrochloride concentration in the preparation to 3% by weight or more.
[0076] An in vivo skin permeability test using Franz cells was conducted on a preparation (patch) in which the liquid preparation of Example 4 (the percutaneous absorption preparation of the present invention) was impregnated with a carrier. The skin used for the test was human skin. The cumulative skin permeation amount (μg / cm 2 ) is shown in Figure 2 .
[0077] The following suggests that a liquid preparation containing 10% by weight of apomorphine hydrochloride has a faster onset of action through skin absorption and can also achieve drug effects in a short time in human skin.
[0078] [Skin irritation test]
[0079] The liquid preparation obtained in Example 3 (the percutaneous absorption preparation of the present invention) was impregnated with a carrier and applied to the surface of rabbit skin for 24 hours, and the skin irritation after peeling was evaluated based on the Draize criteria. As a result, it was found that the skin irritation index PII was 0.1, which was a preparation with sufficiently low skin irritation.
[0080] [Stability test]
[0081] The liquid obtained in Example 3 (the percutaneous absorption preparation of the present invention) was impregnated with a carrier to form a preparation (patch) which was sealed and filled in an aluminum laminate container and stored in a thermostatic chamber at 25°C for 6 months. The results after storage are shown in Table 3. Apomorphine hydrochloride is known to be unstable and easily discolored, but it was confirmed that the percutaneous absorption preparation or patch of the present invention is stable.
[0082] [Table 3]
[0083]
Claims
1. A percutaneous absorption preparation comprising: 3% by weight or more of apomorphine or a salt thereof, Polyols having 6 or less carbon atoms and / or low molecular weight polyethylene glycol, and Propylene carbonate; When the weight of the propylene carbonate is set to 1, the total weight of the polyol and the low molecular weight polyethylene glycol is in the range of 5 to 10, The polyol is one or more selected from propylene glycol, glycerol, and 1,3-butylene glycol.
2. The percutaneous absorption preparation according to claim 1, wherein Contains 4% by weight or more of the apomorphine or a salt thereof.
3. The percutaneous absorption preparation according to claim 1 or 2, wherein The propylene carbonate is contained in an amount within a range of 5 to 40 wt%.
4. The percutaneous absorption preparation according to claim 1 or 2, further comprising an antioxidant.
5. The percutaneous absorption preparation according to claim 4, wherein The antioxidant is sodium metabisulfite.
6. The percutaneous absorption preparation according to claim 1 or 2, further comprising an organic acid or water.
7. The percutaneous absorption preparation according to claim 6, wherein The organic acid is isostearic acid or oleic acid.
8. The percutaneous absorption preparation according to claim 1 or 2, further comprising an emulsifier.
9. The percutaneous absorption preparation according to claim 1 or 2, wherein The dosage form is liquid, gel or ointment.
10. A patch prepared by impregnating a carrier with the percutaneous absorption preparation according to claim 9.
